Samsung Bioepis Signs Commercial Partnership Agreement with Japan's Nipro

A Milestone for Entering the Japanese Biosimilar Market

Samsung Bioepis announced on June 9 that it has signed a partnership agreement with Japan's Nipro Corporation (Nipro) for the commercialization of various biosimilar products, including the Stelara biosimilar (project name SB17).

Kim Kyunga, President of Samsung Bioepis (left), and Yoshihiko Sano, President of Nipro Corporation (right), are taking a commemorative photo after signing a partnership agreement. Photo by Samsung Bioepis

This is the first time that Samsung Bioepis is collaborating with a local company to enter the Japanese market. Under the agreement, Samsung Bioepis will be responsible for product development, manufacturing, and supply, while Nipro will handle sales.

Kim Kyunga, President of Samsung Bioepis, stated, "This partnership agreement marks an important milestone in our entry into the Japanese market. We will work closely with a specialized sales company in Japan, a market with significant biosimilar potential, to further expand patient access to high-quality biopharmaceuticals."

Since its establishment in 2012, Samsung Bioepis has obtained marketing approval for a total of 11 blockbuster biosimilar products. Last year, the company achieved record sales of KRW 1.5377 trillion, rapidly solidifying its position as a leading company in the global biosimilar industry.

This content was produced with the assistance of AI translation services.